Citrate anticoagulation for continuous venovenous hemofiltration.
about
Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developmentsClinical review: use of renal replacement therapies in special groups of ICU patientsRenal replacement therapy in acute kidney injury: controversy and consensusPromoting Kidney Function Recovery in Patients with AKI Requiring RRT.Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Advances in continuous renal replacement therapy: citrate anticoagulation update.Platelet Consumption and Filter Clotting Using Two Different Membrane Sizes during Continuous Venovenous Haemodiafiltration in the Intensive Care Unit.The incidence of thrombocytopenia associated with continuous renal replacement therapy in critically ill patients.Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs.Continuous venovenous hemodiafiltration with a low citrate dose regional anticoagulation protocol and a phosphate-containing solution: effects on acid-base status and phosphate supplementation needsHemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2).Factors affecting outcome in acute hypertriglyceridemic pancreatitis treated with plasma exchange: an observational cohort study.Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial.Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.Anticoagulation, delivered dose and outcomes in CRRT: The program to improve care in acute renal disease (PICARD).Year in review in Intensive Care Medicine 2010: I. Acute renal failure, outcome, risk assessment and ICU performance, sepsis, neuro intensive care and experimentalsRegional citrate anticoagulation for RRTs in critically ill patients with AKI.Clinical experience with nadroparin in patients undergoing dialysis for renal impairment.Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study.Citrate Pharmacokinetics in Critically Ill Patients with Acute Kidney InjuryCitrate for continuous renal replacement therapy: safer, better and cheaper.Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial.Pro/con debate: continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish?Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate?Simplified Citrate Anticoagulation for CRRT Without Calcium ReplacementPutative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalitiesImplementation of continuous renal replacement therapy with regional citrate anticoagulation on a surgical and trauma intensive care unit: impact on clinical and economic aspects-an observational study.Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials.The Effects of High Level Magnesium Dialysis/Substitution Fluid on Magnesium Homeostasis under Regional Citrate Anticoagulation in Critically Ill.Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.Chloride content of solutions used for regional citrate anticoagulation might be responsible for blunting correction of metabolic acidosis during continuous veno-venous hemofiltration.Citrate shows protective effects on cardiovascular and renal function in ischemia-induced acute kidney injury.Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients.Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solutionContinuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational studyBench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice.Good-bye CRRT, here comes SLED? ... not so fast!Regional citrate anticoagulation in patients with liver failure--time for a rethink?Coordination dynamics and coordination mechanism of a new type of anticoagulant diethyl citrate with ca(2+) ions.
P2860
Q21195747-54BFF654-BB1A-4133-8523-3684AAAD7263Q26853350-07A5A20C-E149-479D-A1B2-AD67E7B88322Q26998864-05B677B4-5311-4844-9CB5-BB6F519CF8C8Q30279072-D1AE5AD8-5432-4D4A-AD7F-D4DA9E1703E0Q33399580-D54F6537-8907-407E-AEEE-159798B8B226Q33403996-BC04E6D5-F5D4-4948-8167-00E91D5008E8Q33415569-5669BF37-FB11-484F-8631-90BF84212020Q33423870-2552FB7A-7D02-4A81-BDC3-F07FD8392CE9Q33426850-572E3723-9DE7-424D-A2FE-33E44C646239Q33587210-F5233BB2-C0B2-4D82-B911-B551A6046D35Q33612746-40CBA192-9932-43B5-A2B4-E412D91F07CDQ33752736-319A3B52-F7DD-4B8C-8D3C-4D2B10D10817Q33927822-B49CAA8B-37A7-443D-B272-A9536D867DC3Q34169048-96551159-673C-4C31-9D21-4FDF64E6DED0Q34323157-FF627207-F40A-4A38-BECA-5A0A0D5E5DA6Q34451757-C08C3954-CE3C-4126-A621-8B2D8826190CQ34534501-196D93F2-8A4D-4B22-86A9-A25F589BE798Q34629661-6F66FA41-818D-4F4F-8DC1-39AB1EF647E1Q34630740-7A65068A-75E3-4EAD-888A-89583669F056Q34676665-884826B0-174C-41FD-9C59-486B3066884EQ34792965-9DF6D1EF-F268-4D45-84A6-D8C5EEA60822Q35091035-1DB9571E-81CB-4BE5-8FA3-A7C9C7039BBBQ35190273-6D9EE18A-B239-4620-AC08-E216D245FCA0Q35567092-E8829F40-F2A9-4C35-B1FE-1B193A324CDFQ35567100-94F9B2DE-9AF5-43D9-817C-A5CDBDB49A4BQ35806341-26950C6D-B671-4873-B474-0EC2C1BD1170Q35827976-18E0EBBA-6A90-4440-AD96-43160DB55D36Q35902914-0101F621-06C4-453E-9109-9259B00C4316Q36017130-AFDD30D8-75AD-44B4-BCA0-F947F2363F48Q36071591-30C0E8A3-562A-4D5E-BC4C-7FB37AC44B93Q36104484-CC2CA5B3-74D6-4974-B707-D61F898926DFQ36113753-5720243B-7F42-4DE4-8043-6674E48C5D6AQ36342440-055FA383-2822-436C-9923-EAE70EE3962AQ36633658-39FB5403-EBB6-49F5-83C0-6C44AA4C601EQ36633751-324EC6FC-2733-43F2-B5B3-7263200F8AB7Q36634057-7F6DF9F7-3F14-49A6-BA35-F23B1877262AQ36902584-6377BED0-BE6E-4084-ADF7-A0BA696B5223Q36902623-2BA64DA1-81A9-4D31-9F90-9E5C71F75934Q36928083-C05AE85A-7AE5-4D7A-8BF7-89D5A891CFC9Q37448820-05FD7163-FB20-4302-9F69-2918881FD9C9
P2860
Citrate anticoagulation for continuous venovenous hemofiltration.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Citrate anticoagulation for continuous venovenous hemofiltration.
@ast
Citrate anticoagulation for continuous venovenous hemofiltration.
@en
type
label
Citrate anticoagulation for continuous venovenous hemofiltration.
@ast
Citrate anticoagulation for continuous venovenous hemofiltration.
@en
prefLabel
Citrate anticoagulation for continuous venovenous hemofiltration.
@ast
Citrate anticoagulation for continuous venovenous hemofiltration.
@en
P2093
P1476
Citrate anticoagulation for continuous venovenous hemofiltration.
@en
P2093
Durk F Zandstra
Heleen M Oudemans-van Straaten
Johan I van der Spoel
Jos P J Wester
Matty Koopmans
Peter H J van der Voort
Rob J Bosman
P304
P356
10.1097/CCM.0B013E3181953C5E
P407
P577
2009-02-01T00:00:00Z